Sunitinib as a Second-line Treatment for Patients With Recurrent Small Cell Lung Cancer

NCT00620347 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

OTHER_GOV

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: sunitinib

Sponsor

National Cancer Center, Korea

Collaborators

[object Object]